Agios Pharmaceuticals | AGIO - Debt


Agios Pharmaceuticals reported $35.74M in Debt for its fiscal quarter ending in March of 2026.





Debt Change Date
AbbVie USD 72.86B 5.36B Mar/2026
Agios Pharmaceuticals USD 35.74M 4.46M Mar/2026
Alnylam Pharmaceuticals USD 1.27B 5.33M Mar/2026
Amgen USD 57.32B 2.72B Mar/2026
Arrowhead Research USD 989.46M 676.69M Mar/2026
Astellas Pharma JPY 565.95B 265.47B Mar/2026
AstraZeneca USD 32.24B 1.68B Jun/2026
Bayer EUR 36.45B 2.93B Dec/2025
Biogen USD 8.09B 1.53B Jun/2026
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Bristol-Myers Squibb USD 46.43B 711M Mar/2026
Daiichi Sankyo JPY 300.48B 99.34B Mar/2026
Eli Lilly USD 43.37B 867M Mar/2026
Exelixis USD 169.54M 3.5M Mar/2026
Gilead Sciences USD 22.17B 2.76B Mar/2026
GlaxoSmithKline GBP 19.06B 1.34B Mar/2026
Incyte USD 38.27M 1.16M Jun/2026
Ionis Pharmaceuticals USD 1.91B 425.5M Jun/2026
Merck USD 49.12B 222M Mar/2026
Moderna USD 1.3B 7M Mar/2026
Nektar Therapeutics USD 0 0 Jun/2022
Novartis USD 49.01B 2.02B Jun/2026
Novartis USD 47B 14.98B Mar/2026
Pfizer USD 63.73B 231M Mar/2026
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Regeneron Pharmaceuticals USD 2.71B 400K Jun/2026
Roche Holding CHF 33.03B 1.41B Jun/2025
Sarepta Therapeutics USD 1.04B 3.08M Mar/2026
Vertex Pharmaceuticals USD 1.99B 44M Mar/2026